Novel high-field MRI compatible subdural electrode and acquisition system for recording and stimulation in small animals

摘要 临床前小动物成像为改进做出了宝贵贡献 我们对人脑的理解。多模式成像方法相结合 功能磁共振成像(FMRI)在颅内的应用 脑电(IEEG)提供了全球网络的无与伦比的视角 跨皮质区域的活动，揭示高时间和空间的信息 关于功能连通性及其固有振荡特性的尺度， 在神经科学和医学的许多分支中都是至关重要的。尽管如此 明显的优势，iEEG-fMRI在小动物研究中的使用受到限制。这个 市场上现有的与MRI兼容的小动物头台是 不足以获得高保真的iEEG-fMRI。在这个前提下工作， 该项目的长期目标是开发一个高保真录音的平台 以及对小动物的刺激。我们建议解锁高保真iEEG-fMRI 成像范例利用我们的专利创新的MRI兼容电极- 基于有机可吸收、可拉伸和可整合的网格(PTFOS) 具有明显优势的最佳安全性、灵活性和性能的基板 而不是其他神经网。该申请的第一阶段建议开发HF-2 采集原型将适合动物核磁共振钻孔记录限制和 在马萨诸塞州的高场磁共振成像(9.4Tesla)期间在大鼠身上测试其可行性 综合医院。二期重点增加刺激模块， 将HF-2商业化和小型化到一个很小的前台。

Abstract Preclinical small animal imaging makes valuable contributions to improving our understanding of human brain. Multi-modal imaging approaches to combine functional Magnetic Resonance Imaging (fMRI) with Intracranial Electroencephalogram (iEEG) provides an unparalleled view of the global network activity across cortical areas, revealing information at high temporal and spatial scales about functional connectivity and their intrinsic oscillatory properties, which is of vital importance in many branches of neuroscience and medicine. Despite this clear advantage, the use of iEEG-fMRI is limited in small animal research. The existing MRI compatible headstages on the market for small animals are inadequate to acquire high-fidelity iEEG-fMRI. Working within this premise, the long-term goal of this project is to develop a headstage for high-fidelity recording and stimulation in small animals. We propose to unlock high-fidelity iEEG-fMRI imaging paradigm leveraging our patented innovative MRI-compatible electrode- grid (PTFOS) which is based on organic-absorbable, stretchable, and conformable substrate for optimal safety, flexibility and performance with distinct advantages over other neural grids. Phase I of this application proposes to develop HF-2 acquisition prototype which will fit into animal MRI bore recording constraints and tests its feasibility in rats during high-field MRI (9.4Tesla) at Massachusetts General Hospital. Phase II focuses on adding stimulation module, commercialization and miniaturization of HF-2 into a tiny headstage.